Cargando…

CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T cells are highly successful in the treatment of hematologic malignancies. We recently generated affinity-optimized CD38CAR T cells, which effectively eliminate multiple myeloma (MM) cells with little or no toxicities against nonmalignant hematopoietic cells. The lac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stikvoort, Arwen, van der Schans, Jort, Sarkar, Subhashis, Poels, Renée, Ruiter, Ruud, Naik, Jyoti, Yuan, Huipin, de Bruijn, Joost D., van de Donk, Niels W. C. J., Zweegman, Sonja, Themeli, Maria, Groen, Richard, O’Dwyer, Michael, Mutis, Tuna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196092/ https://www.ncbi.nlm.nih.gov/pubmed/34131635 http://dx.doi.org/10.1097/HS9.0000000000000596

Ejemplares similares

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma
por: Hosny, Mashhour, et al.
Publicado: (2021)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Targeted Therapy With Immunoconjugates for Multiple Myeloma
por: Bruins, Wassilis S. C., et al.
Publicado: (2020)

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL OUTCOME IN ELDERLY MULTIPLE MYELOMA PATIENTS
por: Bruins, Wassilis, et al.
Publicado: (2023)

Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
por: Stikvoort, Arwen, et al.
Publicado: (2016)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma
por: Deshantri, Anil K., et al.
Publicado: (2020)

Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy
por: Erkers, Tom, et al.
Publicado: (2017)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Revisiting the Role of γδ T Cells in Anti-CMV Immune Response after Transplantation
por: Gaballa, Ahmed, et al.
Publicado: (2021)

Shuterin Enhances the Cytotoxicity of the Natural Killer Leukemia Cell Line KHYG-1 by Increasing the Expression Levels of Granzyme B and IFN-γ through the MAPK and Ras/Raf Signaling Pathways
por: Lin, Jen-Tsun, et al.
Publicado: (2022)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

P18 SKIN EXPRESSION OF P16(INK4A), A BIOMARKER FOR CELLULAR SENESCENCE, DOES NOT PREDICT FRAILTY OR TREATMENT OUTCOME IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Smits, F., et al.
Publicado: (2023)

Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
por: Sairafi, Darius, et al.
Publicado: (2016)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome
por: Gaballa, Ahmed, et al.
Publicado: (2016)

Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
por: Rådestad, Emelie, et al.
Publicado: (2018)

Chimeric Leader Peptides for the Generation of Non-Natural Hybrid RiPP Products
por: Burkhart, Brandon J., et al.
Publicado: (2017)

Modulating Bone Regeneration in Rabbit Condyle Defects with Three Surface-Structured Tricalcium Phosphate Ceramics
por: Duan, Rongquan, et al.
Publicado: (2018)

Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines
por: Al-Jamaei, Aisha A. H., et al.
Publicado: (2022)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review
por: Aparicio, Cristina, et al.
Publicado: (2023)

Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
por: Nijhof, Inger S., et al.
Publicado: (2017)

The weeding handbook: a shelf-by-shelf guide
por: Vnuk, Rebecca
Publicado: (2015)

Bone marrow provides an environment that prevents suppression of therapeutic graft-vs.-tumor immunity by regulatory T cells
por: Guichelaar, Teun, et al.
Publicado: (2013)

Modelling Curved Contact Flexible Microstrip Applicators for Patient-Specific Superficial Hyperthermia Treatment Planning
por: Kok, H. Petra, et al.
Publicado: (2020)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

On-shelf circulation of warm water toward the Totten Ice Shelf in East Antarctica
por: Hirano, Daisuke, et al.
Publicado: (2023)

Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
por: Holthof, Lisa C., et al.
Publicado: (2020)

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses
por: Daly, John, et al.
Publicado: (2022)

Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
por: Grote, Stefan, et al.
Publicado: (2020)

Shelf life /
por: Man, Dominic
Publicado: (2002)

Shelf Life
Publicado: (2006)

Book Shelf
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p95eul90cj3ad86v5mi0mblol5